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Abstract Newborn screening (NBS) is justified if early inter-
vention is effective in a disorder generally not detected early in
life on a clinical basis, and if sensitive and specific biochem-
ical markers exist. Experience with NBS for homocystinurias
and methylation disorders is limited. However, there is robust
evidence for the success of early treatment with diet, betaine
and/or pyridoxine for CBS deficiency and good evidence for
the success of early betaine treatment in severe MTHFR defi-
ciency. These conditions can be screened in dried blood spots
by determining methionine (Met), methionine-to-phenylanine
(Met/Phe) ratio, and total homocysteine (tHcy) as a second tier
marker. Therefore, we recommend NBS for cystathionine
beta-synthase and severe MTHFR deficiency. Weaker evi-
dence is available for the disorders of intracellular cobalamin
metabolism. Early treatment is clearly of advantage for pa-
tients with the late-onset cblC defect. In the early-onset type,
survival and non-neurological symptoms improve but the ef-
fect on neurocognitive development is uncertain. The cblC
defect can be screened by measuring propionylcarnitine,
propionylcarnitine-to-acetylcarnitine ratio combined with the
second tier markers methylmalonic acid and tHcy. For the
cblE and cblG defects, evidence for the benefit of early treat-
ment is weaker; and data on performance ofMet, Met/Phe and
tHcy even more limited. Individuals homozygous or com-
pound heterozygous for MAT1A mutations may benefit from
detection by NBS using Met, which on the other hand also
detects asymptomatic heterozygotes. Clinical and laboratory
data is insufficient to develop any recommendation on NBS
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NBS newborn screening
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R4S Region 4 Stork
SAHH S-adenosylhomocysteine hydrolase
tHcy total homocysteine
Introduction
One of the major problems in the evaluation of data on clinical
course and treatment efficacy in rare diseases is the absence of
standardized databases derived from large numbers of patients
assembled in an unbiased manner. Such data on natural course
and benefits of early intervention are essential to support de-
cisions on what to include in newborn screening (NBS)
panels. To meet these needs for a specific group of inborn
errors of metabolism, E-HOD, the European network and reg-
istry for homocystinurias and methylation defects (disturbed
S-adenosylmethionine and S-adenosylhomocysteine ratio)
was started in February 2013 (Table 1, pathways depicted in
Fig. 1). Aims of the project are, among others, the establish-
ment of a disease registry for the collection of clinical, bio-
chemical and genetic data, and the development of guidelines.
The aims above are pursued in this report with respect to
guidelines for NBS for the homocystinurias and methylation
disorders developed on the basis of a systematic review of the
literature, current NBS practice and expert discussions.
Methods
A systematic search of the Pubmed and Cochrane databases
was performed using the search term Bnewbornscreening^ in
combination with every disease addressed by this report. To
evaluate treatment efficacy, publications on clinical course,
outcome and treatment were searched for.
After exclusion of publications containing no relevant in-
formation, study design and level of evidence was evaluated
for 103 publications according to the BGrading of Recommen-
dations Assessment, Development and Evaluation (GRADE)
working group (http://www.gradeworkinggroup.org/)^
approach. Furthermore, data on metabolite concentrations in
dried blood spots (DBS) at the time of screening obtained
from 486 pat ients wi th subsequent ly conf i rmed
homocystinurias and methylation disorders as well as cumu-
lative data on distribution of analytes in healthy newborns and
clinically validated target ranges for cut-off values were re-
trieved from the multi-center study BRegion 4 Stork^ (R4S)
website (McHugh et al 2011). In addition, EHOD partners
were asked to contribute their non-published experience with
NBS for the disorders of interest. The guidelines were
established based on the literature evaluation and expert dis-
cussions following the GRADE approach. Expert consensus
was targeted for each disease on the following key questions:
a) Is the natural course of the disease severe?
b) Is treatment generally beneficial?
c) Is early intervention more effective?
d) Are robust, valid and reliable methods, screening ap-
proaches and strategies available?
Results
Classical homocystinuria or cystathionine-ß-synthase
deficiency
Clinical findings
In classical homocystinuria or cystathionine-ß-synthase
[CBS] deficiency, the condensation of serine and homocyste-
ine (Hcy) to form cystathionine is disturbed as well as other
processes such as the production of hydrogen sulphide from
other substrates. Pyridoxal 5′-phosphate formed from dietary
vitamin B6 is the essential cofactor of the enzyme. The true
incidence of CBS deficiency is unknown; it has been estimat-
ed at 1:344.000 worldwide (Mudd et al 1985) but due to dif-
ferent population frequencies and ascertainment methods, re-
ports on CBS incidence vary largely. Molecular epidemiolog-
ical studies predict frequencies between 1:6.400 and 1:20.500
in European populations (Gaustadnes et al 1999; Refsum et al
2004; Janosík et al 2009).
Biochemical hallmarks of CBS deficiency are highly ele-
vated concentrations of plasma total homocysteine (tHcy)
combined with low plasma cystine or total cysteine, high nor-
mal to elevated plasma methionine (Met), low normal to
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decreased cystathionine, and a grossly abnormal
cystathionine/Met ratio (Stabler et al 2013; Bártl et al 2014).
Generally, patients present with ectopia lentis and myopia,
mental retardation, marfanoid habitus and osteoporosis,
thromboembolic events, developmental and behavioral prob-
lems (Mudd et al 1985). If diagnosis is delayed, significant
long-term morbidity must be expected (Naughten et al 1998;
Yap and Naughten 1998). Milder forms and especially the
pyridoxine-responsive variants of the disease due to specific
mutations such as c.833 T>C (p.I278T) may manifest later in
adulthood e.g., with thromboembolic events or may even re-
main asymptomatic until adulthood (Skovby et al 2010;
Magner et al 2011).
In the pyridoxine-responsive patients, variable doses of
pyridoxine elicit near-normalization of biochemical parame-
ters (Mudd et al 1985). Patients with the more severe, pyri-
doxine non-responsive form of the disease are generally treat-
ed with a Met restricted diet mostly combined with
supplementing amino acid mixtures enriched with cysteine.
Many patients are treated with oral betaine, which provides
methyl groups for homocysteine [Hcy] remethylation to Met
(Adam et al 2013). Treatment encompassed a combination of
diet and betaine in 61 %, betaine alone in 34 % and diet alone
in 5 % of 181 European pyridoxine non-responsive CBS pa-
tients (Adam et al 2013).
Despite the variability of approaches, treatment effectively
reduces morbidity, especially when initiated early. A
significant reduction of vascular morbidity has been observed
in 158 treated patients (Yap et al 2001). While 112 vascular
complications were predicted on the basis of historical data
from untreated CBS deficient patients, only 17 vascular com-
plications occurred in 12 patients (Yap et al 2001). Thirteen
CBS patients identified by NBS and with good compliance to
treatment had normal full-scale IQ results (mean 105.8) in
contrast to six poorly compliant (mean IQ 80.8) and
two untreated patients (IQ 52 and 53) (Yap et al
2001). These findings are supported by 11 patients di-
agnosed on NBS who developed no somatic symptoms
and had a normal IQ (Walter et al 1998). In 14 late
diagnosed patients, all had lens subluxation/dislocation
and impaired vision at diagnosis and eye disease
progressed with less strict adherence to treatment. In
contrast, 15 early treated patients had no evidence of
lens subluxation and better visual acuity (Mulvihill
et al 2001).
Recommendation The severe form of CBS deficiency is de-
fined by its significant morbidity (milder forms are also
known). A large subgroup of patients is responsive to pyri-
doxine administration. Low methionine/low protein diet
(mostly combined with methionine–free and cysteine
enriched amino acid mixture) and/or betaine administration
is effective in pyridoxine non-responsive CBS deficiency.
Normal cognitive development and prevention of physical
Fig. 1 Homocystinurias and methylation disorders: metabolic pathways
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complications is possible in patients detected by NBS and
treated early with continuous strict compliance.
Methods for NBS in CBS deficiency
Since the 1970s NBS for CBS deficiency has been based on
the detection of increased Met concentration in dried blood
spots (DBS) (Chace et al 1996; Mudd 2011). Long-term ex-
perience with the NBS for CBS deficiency exists namely in
Ireland, Italy, Portugal, and some U.S. states (McHugh et al
2011; Naughten et al 1998; Peterschmitt et al 1999; Accinni
et al 2003;Martins et al 2012). Varying proportions (20–50%)
of missed pyridoxine non-responsive cases have been report-
ed with different Met cut-off values used (Naughten et al
1998; Gan-Schreier et al 2010). Lowering of the Met cut-off
from 138 to 67 μmol/L doubled the detection rate of CBS
deficiency (Peterschmitt et al 1999). Accordingly, Met cut-
off values as low as 40 μmol/L have been proposed to yield
higher sensitivity (McHugh et al 2011; Turgeon et al 2010).
Sensitivity is also increased by using the Met/Phe ratio which
adjusts for protein intake (Bowron et al 2005). In conclusion,
the primary factor driving sensitivity is the selection of as low
as possible cut-off values for Met and Met/Phe ratio.
Although the pyridoxine responsive form of CBS deficien-
cy is common in various populations and represented 44 % of
patients in the historical cohort of 629 patients (Mudd et al
1985), only 3–13 % of patients detected by NBS reported in
the literature were pyridoxine responders (Mudd et al 1985;
Janosík et al 2009). This marked discrepancy indicates that
NBS programs using Met as the primary marker most likely
fail to detect the majority of patients with pyridoxine respon-
sive disease (Mudd 2011).
Specificity of Met as the primary marker is poor since
blood concentrations also increase in other disorders, e.g.,
liver disease, MATI/III, GNMT and SAHH deficiencies, and
tyrosinemia type I (Mudd 2011). Specificity may be improved
by quantifying tHcy in DBS as a second-tier marker (Bártl
et al 2014; Turgeon et al 2010; Alodaib et al 2012) leading
to a fivefold reduction of the false positive rate compared to
the period when only Met at a cut-off of 40 μmol/L was used
(Bowron et al 2005).
Data on 124 CBS deficient patients ascertained by NBS
show wide variation of the Met concentration in DBS with a
clearly increased median of 103 μmol/L compared to the me-
dian of 20 μmol/L in healthy neonates (Table 3) (McHugh
et al 2011). A target cut-off value for Met to differentiate the
99th centile in healthy newborns from the 5th centile in con-
firmed true positive cases recommended by R4S is in the
range between 39 and 50 μmol/L. The Met/Phe ratio has
slightly better performance characteristics. Data on tHcy in
DBS as a secondary marker at the time of screening is avail-
able from 31 CBS deficient patients showing a clear distinc-
tion between cases (median tHcy 40 μmol/L) and controls
(6 μmol/L). When tHcy is measured on the same specimen
as a second tier test, calculating the Met/tHcy ratio may help
differentiate the patients with CBS deficiency from MATI/III
deficient individuals (see Table 3).
The measurement of tHcy as primary NBSmarker has only
been used in the native Qatari population due to technical
requirements and high costs (Gan-Schreier et al 2010). Mo-
lecular genetic testing is feasible and may be an option for
high-risk populations with a limited number of prevalent mu-
tations. However, this approach will miss individuals carrying
other mutations (Gan-Schreier et al 2010).
Recommendation NBS for CBS deficiency can be performed
by detecting elevated methionine, methionine-to-
phenylalanine ratio and/or hyperhomocysteinemia in dried
blood spots. However, total homocysteine has only exception-
ally been used as a primary marker. Sensitivity of methionine
as a primary marker for pyridoxine non-responsive CBS defi-
ciency is limited and inversely related to the chosen cut-off
concentrations of methionine. For the pyridoxine responsive
form of the disease sensitivity is largely unknown and proba-
bly low. Specificity of methionine as a primary marker may be
substantially increased by analyzing total homocysteine as a
second tier marker and calculating the Met/tHcy ratio.
The combined remethylation defects cblC, cblF, cblJ,
and cblD-MMA-Hcy
Clinical findings
The cblC defect, caused by mutations in the MMACHC gene
is the most common of these defects (Lerner-Ellis et al 2009).
Mutations in the LMBRD1 gene cause the cblF defect (Rutsch
et al 2009), and ABCD4mutations the cblJ defect (Coelho et al
2012). Depending on type and location of the mutation in the
MMADHC gene, the cblD defect either presents as isolated
methylmalonic acid (MMA)-uria (cblD-MMA, beyond the
scope of this report), combined MMA and homocystinuria
(cblD-MMA-Hcy, resembling the cblC, cblF and cblJ defects)
or isolated homocystinuria (cblD-Hcy, clinically
indistinguishable from the cblE or cblG defect, addressed
below) (Jusufi et al 2014). All defects affect the synthesis of
methylcobalamin, the co-factor for the cytosolic enzyme me-
thionine synthase, and of adenosylcobalamin, the coenzyme
for the intramitochondrial enzyme methylmalonyl-CoA mu-
tase, which metabolizes MMA (Fig. 1). Thus lowMet, elevat-
ed tHcy, propionylcarnitine and MMA are biochemical hall-
marks of the disorders (McHugh et al 2011; Fowler 1998).
Main clinical symptoms of the early-onset form of the cblC
defect (<12 months, 88 % of cases) (Fischer et al 2014) in-
clude failure to thrive, macrocytic anemia, muscular hypoto-
nia, developmental delay, dysmorphic features, thinned cor-
pus callosum, hydrocephalus, hemolytic uremic syndrome,
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and decreased visual acuity due to pigmentary retinopathy but
no lens dislocation (Rosenblatt et al 1997; Weisfeld-Adams
et al 2013; Fischer et al 2014). Late-onset patients may present
any time during childhood or adult life, typically with various
combinations of myelopathy, dementia, psychiatric symp-
toms, hemolytic-uremic syndrome, thromboembolism, and
pulmonary hypertension; retinopathy occurs rarely (Fischer
et al 2014; Huemer et al 2014a).
Treatment of the cblC defect — which has also been ap-
plied in cblF, cblJ, and cblD-Hcy-MMA defects— consists of
intramuscular hydroxycobalamin (OH-Cbl), oral betaine and
folate, rarely combined with Met supplementation. Carnitine
is often added but has no proven effect (Martinelli et al 2011).
Dosages of medications vary considerably (Fischer et al 2014;
Carrillo-Carrasco et al 2012).
In early-onset cblC patients, overall survival, hematologi-
cal symptoms, and failure to thrive improve while eye disease
and cognitive impairment often progress under treatment
(Martinelli et al 2011; Fischer et al 2014). Despite identifica-
tion by NBS and early treatment, 11/12 patients showed de-
velopmental delay, 8/9 brain pathologies, 10/11 muscular hy-
potonia, and 9/12 nystagmus at a mean age of 50 months
(Weisfeld-Adams et al 2013). However, from a screened and
early treated cohort of 13 patients from Tuscany, the ten pa-
tients subjected to psychometric testing achieved a mean DQ
of 80 or IQ of 85 compared to a mean DQ/IQ of 45 and 66 in
18 clinically diagnosed patients (mean age at diagnosis:
54 days). Only 7/13 screened and early treated patients devel-
oped the characteristic eye disease compared to 11/13 clini-
cally diagnosed early-onset patients (Pasquini 2014, personal
communication).
In most late-onset cblC patients, dementia, renal function,
myelopathy, and axonal neuropathy improve on treatment.
Long-lasting disease before treatment initiation correlates
with incomplete recovery and residual pathologies (Huemer
et al 2014a).
Clinical information is available for less than twenty
patients with the cblF defect. Three patients died at 5,
9, and 10 months, respectively (Shih et al 1989;
Bowron et al 2005; Alfadhel et al 2011). In some early
treated patients, neurocognitive outcome was good
(Miousse et al 2011; Armour et al 2013), while in
others severe developmental delay was present (Gailus
et al 2010; Alfadhel et al 2011). For the cblJ defect
(Coelho et al 2012), clinical information on treatment
outcome is extremely limited. Two patients reportedly
responded well to treatment with methylcobalamin
(Kim et al 2012). In the reported cblD-Hcy-MMA cases,
a broad spectrum of responses to treatment has been
observed ranging from fatal progression of symptoms
(Miousse et al 2009) to improved (Suormala et al
2004; Miousse et al 2009) to even nearly normal devel-
opment (Suormala et al 2004) (Table 2).
Recommendation Screening for the cblC defect should be
considered since in the early-onset CblC defect response to
treatment has been observed for non-neurological symptoms
with improved overall survival. The impact of early treatment
on neurocognitive development and retinopathy is unclear.
For late-onset patients treatment is mostly beneficial, especial-
ly when initiated before irreversible organ damage has oc-
curred. The present knowledge allows no conclusion
concerning the benefit of early treatment for the cblD-Hcy-
MMA, cblF and cblJ defects.
Methods for NBS in the combined remethylation defects
Newborn screening for these defects has used the primary
markers propionylcarnitine (C3), propionylcarnitine/
acetylcarnitine (C3/C2) ratio, Met, and Met/Phe ratio. The
R4S data indicate that the sensitivity of C3/C2 is superior to
Met and Met/Phe. Indeed, the use of cut-off values for C3/C2
between 0.18 and 0.20 μmol/L differentiates between the 99th
centile in healthy newborns and the 5th centile of cases with
cblC, cblD-Hcy-MMA and cblF (McHugh et al 2011). In
contrast, both Met and Met/Phe will miss a considerable pro-
portion of cases if used as a primary marker alone (McHugh
et al 2011) (Table 3).
The specificity of C3 and/or C3/C2 for detecting these
diseases is generally low (la Marca et al 2007; Turgeon et al
2010) since they also detect nutritional imbalances (including
maternal vitamin B12 deficiency) or other inborn errors of
metabolism (Scolamiero et al 2014). Low Met has been pro-
posed as a possible secondary marker (Weisfeld-Adams et al
2010), but due to the above mentioned shortcomings, other
second tier strategies have been developed, applying isolated
or simultaneous measurement of MMA, methylcitric acid and
tHcy (Alodaib et al 2012; la Marca et al 2007; Tortorelli et al
2010; Fu et al 2013). While methylcitric acid does not differ-
entiate cblC/cblD patients from controls, the positive predic-
tive value substantially increased from 4 to 100 % by mea-
surement ofMMA and from 11 to 36% bymeasuring tHcy (la
Marca et al 2007; Turgeon et al 2010).
Recommendation NBS for the cblC defect can be performed
by identification of elevated propionylcarnitine with a high
propionylcarnitine/acetylcarnitine ratio. Low methionine or
low methionine/phenylalanine ratio are less sensitive. Sensi-
tivity of propionylcarnitine and propionylcarnitine/
acetylcarnitine ratio for detecting mild forms of the cblC de-
fect is unknown. Specificity of biomarkers substantially in-
creases by analyzing methylmalonic acid and/or total homo-
cysteine in DBS as a second tier test. It can be anticipated that
the same markers are useful for the detection of cblD-Hcy-
MMA, cblF or cblJ disorders but efficacy and feasibility of
screening for these three disorders is unknown. It should be
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noted that by using these markers, maternal vitamin B12 de-
ficiency might be detected.
Isolated remethylation defects: the cblE, cblG, and cblD-Hcy
defects, and severe MTHFR deficiency
Clinical findings
The cblG defect affects the enzyme methionine synthase
(MTR) while methionine synthase reductase (MTRR) is de-
fective in the cblE defect (Watkins and Rosenblatt 2012). The
clinically similar cblD-Hcy defect was discussed above. All
defects impair the remethylation of Hcy to Met and result in
elevated tHcy and low normal to low Met (Stabler et al 2013;
Huemer et al 2014b).
The clinical pattern of the cblE and the cblG defect is in-
distinguishable. Mostly, initial symptoms evolve in the first
year of life or in early childhood (Zavadakova et al 2005).
Macrocytic and/or megaloblastic anemia, failure to thrive
and feeding difficulties, cognitive dysfunction, nystagmus,
impaired visual acuity but no lens dislocation, and seizures
are frequent. Microangiopathy and hemolytic uremic
syndrome have only very rarely been described (Huemer
et al 2014b). A subgroup of three patients from the
Iberian Peninsula presented with isolated macrocytic
anemia (Vilaseca et al 2003).
Treatment encompasses folic or folinic acid, betaine and a
variety of cobalamin (OH-Cbl, cyano- or methylcobalamin)
preparations. Mostly tHcy and Met as well as macrocytic ane-
mia (Fowler et al 1997; Vilaseca et al 2003) and
neurocognitive performance (Fowler et al 1997; Harding
et al 1997; Vilaseca et al 2003; Müller et al 2007; Schiff
et al 2011) respond well to treatment. In four patients, a pos-
itive impact of early treatment on outcome has been observed
(Müller et al 2007; Schiff et al 2011). However, in a series of
nine cblE patients, the overall impact of treatment on
neurodevelopmental disabilities and eye disease was Bat most
moderate^ (Zavadakova et al 2005). Eye disease seems not to
respond to treatment (Huemer et al 2014b).
Severe methylenetetrahydrofolate reductase (MTHFR) de-
ficiency also results in defective methylation of Hcy to Met.
The enzyme MTHFR catalyzes the reduction of 5,10 methy-
lenetetrahydrofolate to 5-methyltetrahydrofolate, which
serves as a methyl donor for the methylation of Hcy to Met
(Fattal-Valevski et al 2000). In addition to elevated tHcy and
decreased Met the folate concentrations in plasma and espe-
cially in CSF are decreased in severe MTHFR deficiency
(Thomas and Rosenblatt 2005; Stabler et al 2013). As in the
combined defects, due to the enhanced flux through the
transsulfuration pathway, plasma cystathionine (median
1192 nmol/L) is grossly elevated in patients compared to con-
trols (median 157 nmol/L) (Stabler et al 2013).
Table 2 Disease course and treatment response in homocystinurias and methylation disorders
Disease Disease course Response to treatment
CBS deficiency B6-non responsive Severe Early, strict treatment results in favorable physical and
cognitive outcome.
CBS deficiency B6-responsive Mild to asymptomatic Good response to pyridoxine
cblC defect Severe Early-onset:
Survival, hematological and microangiopathy
symptoms responsive.
Neurological, opthalmological and developmental
problems often ongoing
Late-onset:
Predominantly responsive, residual myelopathy/neuropathy
frequent in prolonged untreated courses
cblD-Hcy defect
cblD-MMA-Hcy defect
Severe Variable, very limited data
cblF defect Severe Variable, very limited data
cblJ defect Severe Variable, very limited data
Severe MTHFR deficiency Severe Early betaine treatment is beneficial
cblE and cblG defect Severe Treatment seems beneficial in a majority of patients
but response is variable. Individual case reports
encourage early treatment
MAT I/III deficiency, heterozygous individuals Predominantly benign Generally good without treatment
MAT I/III deficiency, compound heterozygote
and homozygote individuals
White matter disease, cognitive
impairment observed
Methionine-lowering treatment may be beneficial
but data is very limited
GNMT deficiency Predominantly benign Generally good without treatment
SAHH deficiency Severe Variable, very limited data
ADK deficiency Severe Unknown
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In severe MTHFR deficiency, developmental delay, sei-
zures, and movement disorders are frequent in children. Ado-
lescents and adults may present with psychiatric symptoms,
neuropathy or thromboembolic events. Retinopathy has only
rarely been reported (Thomas and Rosenblatt 2005) but data
from a mouse model show impaired retinal function
(Lawrance et al 2011). Megaloblastic and/or macrocytic ane-
mia is usually absent (Thomas and Rosenblatt 2005). Treat-
ment with folate, folinic acid, Met, pyridoxine, and different
cobalamin preparations has generally been considered unsuc-
cessful (Thomas and Rosenblatt 2005). However, Met supple-
mentation improved the course in an early onset case (Abeling
et al 1999). In a systematic review including 36 patients, the
positive impact of early betaine treatment on outcome in early-
onset patients was shown (Diekman et al 2014). Five early
treated patients survived with normal psychomotor de-
velopment while nine of ten non-treated and two late
treated patients died. In families with one or more de-
ceased siblings, none of the treated but all untreated
children died. Psychomotor development was impaired
in all children with delayed treatment onset, despite sta-
bilization from introduction of treatment (Diekman et al
2014) (Table 2).
Recommendation NBS for severe MTHFR deficiency is rec-
ommended since early betaine administration is associated
with a positive outcome. NBS for the cblD-Hcy, cblE, and
cblG defects can be considered since in the majority of clini-
cally diagnosed patients, treatment seems beneficial and there
is some evidence for an added benefit of early treatment.
Methods for NBS in the cblD-Hcy, cblE, and cblG defects,
and severe MTHFR deficiency
Neonatal screening for these disorders became possible only
after the introduction of tandem mass spectrometry for deter-
mination of decreased Met concentration in DBS (Chace et al
1996). Data on 18 remethylation cases were available in R4S
(four MTHFR, one cblG, and one cblE and 12 non-classified
cases). The Met concentration in the DBS was decreased to a
median of 5.91 μmol/L in the patients, with no overlap with
healthy newborns (Table 3). In addition, both the Met/Phe
ratio (Bowron et al 2005) and the second-tier marker tHcy
clearly differentiate patients from controls (Tortorelli et al
2010; McHugh et al 2011).
In theory, tHcy can be employed as the primary screening
marker but there are no published data on its use. There are no
long-term data on efficacy of screening programs for these
disorders (Tortorelli et al 2010) owing to their rarity and low
proportion of screening programs addressing decreased Met
or Met/Phe ratio (in R4S, 162 laboratories have listed a high
cut-off for methionine, but only 73 have a low cut-off value).
Recommendation Neonatal screening for the cblD-Hcy,
cblE, and cblG defects, and for MTHFR deficiency ap-
pears to be possible by detecting a decreased methio-
nine and methionine-to-phenylalanine ratio in DBS
followed by analysis of total homocysteine as a second
tier marker. Efficacy and feasibility of screening for
these disorders is largely unknown.
Methionine adenosyltransferase deficiency
Clinical findings
Methionine adenosyltransferase (MAT) catalyses the forma-
tion of S-adenosylmethionine (AdoMet) fromMet. Three var-
iant forms (MAT I, II and III) of the enzyme have been de-
scribed. The MAT I and III — encoded by a single gene
(MAT1A) — are expressed mainly in liver. The MATII is
expressed ubiquitously in extrahepatic tissues and seems
to play a pivotal role in maintaining whole body
AdoMet homeostasis. Homozygosity or compound het-
erozygosity for MAT1A mutations and heterozygosity for
some mutations result in hypermethioninemia without
elevation of AdoMet concentrations. Inheritance of this
biochemical trait may thus be autosomal recessive or
autosomal dominant (Baric 2009).
There is evidence that a small number of individuals ho-
mozygous or compound heterozygous for MAT1A mutations
develop myelination defects or white matter disease and some
of these patients are cognitively impaired. These clinical signs
have been related to persistent very high Met concentrations
and/or to AdoMet deficiency in the brain (17, 63). It is advis-
able to monitor these patients closely and to consider intro-
duction of a Met restricted diet or AdoMet supplementation.
The available evidence suggests that AdoMet supplementa-
tion may normalize existing white matter changes (Surtees
et al. 1991).
However, the most common autosomal dominant form of
hypermethioninemia detected by neonatal screening is caused
by heterozygosity for the mutation c. 791G>A (p.R264H).
Since the clinical course in these individuals is generally be-
nign (Baric 2009; Mudd 2011), the impact of a protein-
controlled diet cannot clearly be evaluated (Couce et al
2013) and the usefulness of early detection of these individ-
uals is questionable (Mudd 2011; Blom 2014, personal
communication) (Table 2).
Recommendation In individuals heterozygous for MAT I/
III deficiency, treatment seems not to be necessary. Pa-
tients homozygous/compound heterozygous for MAT I/
III mutations should be monitored closely and may re-
quire intervention. Data on the benefit of early interven-
tion is lacking.
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Methods for NBS in MATI/III
Most MAT I/III deficient individuals were originally identi-
fied by NBS programs targeting CBS deficiency (Mudd 2011)
and the number of detected individuals substantially increased
with use of lowerMet cut-off values between 45 and 54μmol/
L (Martins et al 2012). The incidence is especially high in the
Galicia region of Spain and in Portugal (1:26.000-1: 28.163),
mostly due to heterozygosity for the p.R264H mutation (Mar-
tins et al 2012; Couce et al 2013). The DBS concentrations of
Met in 143MAT I/III deficient individuals (including carriers)
in the R4S database reached a median of 103 μmol/L
compared to the median of 20 μmol/L in healthy neo-
nates (McHugh et al 2011). A target cut-off value for
Met to differentiate between the 99th centile in healthy
newborns from the 5th centile in confirmed true positive
cases is consequently in the range between 39 and
50 μmol/L (Table 3). The Met/Phe ratio has similar
performance characteristics (McHugh et al 2011). Differ-
entiation between MATI/III and CBS deficiency based
on Met concentrations is not possible. However, deter-
mination of tHcy concentration as second tier strategy
and then calculating the Met/tHcy ratio may discrimi-
nate between CBS and MATI/III deficiency; a simple
and effective approach is to apply the dual scatter plot
functionality available on the website of the R4S col-
laborative project (Table 3).
Recommendation Individuals with MATI/III deficiency have
been predominantly detected in NBS programs for CBS defi-
ciency due to increased methionine concentrations. The ma-
jority of these newborns are heterozygotes for the mutation
c.791G>A and the benefit of detecting these individuals is
questionable. At present, there is no primary marker to differ-
entiate between MATI/III and CBS deficiency. Data on the
Met/tHcy ratio to differentiate between these two conditions
are promising but limited.
Glycine-N-methyltransferase deficiency,
S-adenosylhomocysteine hydrolase deficiency and adenosine
kinase deficiency
An o t h e r d i s o r d e r c h a r a c t e r i z e d b y i s o l a t e d
hypermethioninemia is glycine-N-methyltransferase
(GNMT) deficiency, which has only been described in three
individuals. GNMT transfers a methyl group from S-
adenosylmethionine to glycine and thus synthesizes sarcosine.
Deficiency of the enzyme results in gross elevation of AdoMet
and Met concentrations. GNMT deficiency seems to be a rel-
atively benign disorder presenting with mild hepatomegaly or
moderately elevated liver transaminases (Baric 2009). At pres-
ent, the rarity and the benign course of the condition do not
support inclusion in NBS programmes (Mudd 2011).
The enzyme S-adenosylhomocysteine hydrolase (SAHH)
catalyses the hydrolysis of S-adenosylhomocysteine to Hcy
and adenosine. SAHH deficiency has been described in seven
patients (Honzík et al 2012). Biochemical findings include
grossly increased S-adenosylhomocysteine with elevation of
S-adenosylmethionine and Met while tHcy may be normal or
mildly elevated. The clinical course in the first male index
patient from Croatia revealed a severe disease with
myelination disorder and low IQ, hepatopathy and myopathy
with elevated creatine kinase. The pathogenesis of myopathy
in SAHH deficiency is at present not completely understood.
While Met restriction had a positive impact on neurocognitive
symptoms even in the index patient and improved the
course significantly in the patient’s two early diagnosed
and treated brothers, myopathy persisted in all cases
(Barić et al 2005; Baric 2009). In another patient, treat-
ment from the age of 5 months to 5 years failed to
prevent clinical symptoms (Baric 2009; Mudd 2011).
Recently two siblings with hydrops fetalis and fatal out-
come have been reported (Grubbs et al 2010),
underlining the severity of the disease.
The enzyme ADK catalyzes the phosphorylation of aden-
os ine , wh i ch i s p roduced by hyd ro lys i s o f S -
adenosylhomocysteine by SAHH. When adenosine is not fur-
the r me tabo l i zed , i t s accumula t ion inh ib i t s S -
adenosylhomocysteine hydrolase leading also to an increase
of the upstreammetabolites S-adenosylmethionine and methi-
onine (Bjursell et al 2011). Until now adenosine kinase
(ADK) deficiency has been described in six patients: two
Swedish siblings and two related pairs of Malaysian siblings
with severe developmental delay, macrocephaly, epilepsy, and
abnormal liver function. One patient died at the age of
10 years. All patients shared the biochemical pattern of ele-
vated methionine, S-adenosylmethionine, and S-
adenosylhomocysteine levels in the presence of normal/
slightly elevated tHcy similar to SAHH deficiency. The detec-
tion of increased urinary adenosine may be useful to differen-
tiate this defect from SAHH deficiency, in which elevated
creatine kinase activity can also be expected. Methionine re-
striction may be beneficial in some patients (Mudd 2011).
Patients may be identified by NBS programs based on
elevated Met (Buist et al 2006), however no targeted
NBS approaches for SAHH and ADK deficiencies have
been reported so far.
Recommendation GNMTappears to be a benign condition. In
the very small numbers of patients described, SAHH and
ADK deficiency are predominantly severe disorders. Present
knowledge allows no conclusive statement concerning the
benefit of early treatment for SAHH and ADK deficiency.
Neonatal screening for SAHH and ADK deficiency cannot
be recommended at this stage due to lack of data and validated
screening strategies.
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Conclusion
Selection of diseases for NBS must be driven by clinical ar-
guments— a severe disease, generally not detectable early in
life on a clinical basis, feasible and effective treatment, and a
better outcome in early treated individuals meets accepted
criteria for inclusion into a NBS program (Wilson and Jungner
1968). However, the evidence for efficacy of treatment in the
homocystinurias and methylation disorders is limited due to
small series of subjects with different genotypes, varying treat-
ment, and inconsistent follow-up strategies. Particularly, time
of initiation of treatment and the use, dosage, and intervals of
application of drugs are far from uniform.
However, despite the above-mentioned limitations of clin-
ical data, there is robust evidence for successful treatment and
improved outcome by early treatment for CBS deficiency, and
to a lesser extent for MTHFR deficiency and the cblC defect.
In CBS deficiency, good outcome in individuals identified by
NBS is consistently reported even from various centers in-
cluding patients with a variety of CBS mutations and despite
a large variability in treatment practice (Naughten et al 1998;
Walter et al 1998). In MTHFR deficiency, the clear clinical
effect of early treatment with betaine is an important
supporting evidence for screening (Diekman et al 2014). In
the late-onset cblC defect, treatment response is seen in almost
all patients but residual disease manifestations are frequent in
patients with long duration of clinical abnormalities before
treatment initiation (Huemer et al 2014a). Evidence for effica-
cy of early treatment is less clear for the early-onset cblC
defect in which survival, hematological symptoms, and feed-
ing problems often improve, while the effect on
neurocognitive development and retinopathy is less encourag-
ing (Weisfeld-Adams et al 2013).
If screening for these disorders is advisable from a clinical
point of view, robust, applicable, and widely accepted primary
and secondary markers must be used. The respective markers
and ratios should be developed and their utility tested by com-
bining a large amount of data and by application of post-
analytical interpretative tools (Marquardt et al 2012; Hall
et al 2014). Algorithms and cut-offs for markers based on
small isolated case series have a significant risk of bias and
may be misleading. However, even with the use of large sam-
ple numbers the selection of reliable cut-off values for NBS
based on comparing data from patients detected by the NBS
methods and values from healthy newborns is not trivial. Very
little data is available on missed cases and milder forms of the
screened diseases, which may manifest years or even decades
later. Therefore, it must be kept in mind that NBS markers
reflect the present state of the art, which is temporary and
may change in the future due to technological advances and
improved knowledge.
For the other disorders addressed by this review, there is
either only weak evidence for a response to treatment and for
the specific value of early treatment [cblE and cblG defects]
(Vilaseca et al 2003; Zavadakova et al 2005), or insufficient
data to evaluate treatment outcome [cblD, cblF, cblJ, GNMT,
SAHH, and ADK deficiency]. It must be emphasized that
NBS programs targeting CBS, MTHFR or cblC will most
probably identify also subjects with other homocystinurias/
methylation disorders with uncertain clinical relevance and
that biochemical algorithms to differentiate between all these
disorders must be established. On one hand, this will allow a
more differentiated view regarding the benefit of early detec-
tion and treatment for these disorders and facilitate genetic
counselling for families with severely affected children. On
the other hand, subjects requiring no treatment and follow-up
may also be detected. A paradigm for this process is the MAT
I/III defect for which data on clinical severity are conflicting.
Heterozygosity for specific MAT1A mutations is considered
benign and these individuals should not but will be picked up.
However, a small but significant number of individuals homo-
zygous or compound heterozygous forMAT1Amutations may
develop clinical complications and may benefit from
treatment.
To improve the overall knowledge on homocystinurias and
methylation disorders, studies on the natural course, treat-
ment, and outcome following a structured scheme are needed.
The E-HOD registry is collecting data on a large number of
patients to create a large, standardized database and thereby
facilitate and support considerations on whether to recom-
mend inclusion or exclusion of these disorders into/from
NBS panels.
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